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Objective: The optimal treatment for patients with uncomplicated chronic Stanford type B aortic dissections (chTBADs) is
still matter of debate. The purpose of this study was to design a decision tool to guide the surgeon in determining the
preferred treatment option.
Methods: A Markov decision-analysis model compared chTBAD patients treated with initial open surgical repair (OSR),
thoracic endovascular aortic repair (TEVAR), and optimal medical therapy (OMT), followed during follow-up by OSR
(OMT-OSR) or TEVAR (OMT-TEVAR), if indicated. Procedural risks, aortic growth and rupture rates, outcomes, and
quality of life values were derived from the best available evidence in the literature. A chTBAD treatment strategy decision
tool was developed, including the four key variables of age, sex, surgical risk, and maximum initial aortic diameter.
Primary outcome was quality-adjusted life-years (QALYs).
Results: For the reference patient cohort, 55-year-old men with chTBAD with a maximum aortic diameter of 5.0 cm,
medium risk for surgery, and a threshold for surgery of 6.0 cm during follow-up, OSR yielded higher QALYs, with 10.06
QALYs (95% credibility interval [CI], 9.52-10.56 QALYs) vs 9.92 QALYs (95% CI, 9.23-10.58 QALYs) after TEVAR
and 9.64 QALYs (95% CI, 9.38-9.88 QALYs) and 9.40 QALYs (95% CI, 9.11-9.69 QALYs) for OMT-OSR and OMT-
TEVAR. The difference between OSR and OMT-OSR was 0.42 QALYs (95% CI, 0.01-0.81 QALYs) and between
TEVAR and OMT-TEVAR was 0.52 QALYs (95% CI, 0.04-0.68 QALYs). This showed that intervention is preferred
over OMT. A change of the four variables resulted in a change of preferred treatment. In general, OSR was the preferred
treatment in younger patients with a larger aortic diameter and in low-risk patients. TEVAR was preferred in elderly
patients with large aortic diameter and if the aortic diameter threshold for repair decreased. OMTwas the optimal therapy
in high-risk patients, elderly patients, or in patients with small aortic diameters.
Conclusions: This decision-analysis model shows that there is no “one-size-ﬁts-all” treatment for uncomplicated chTBADs.
For the reference patient cohort, intervention is preferred over OMT. Age is the most important deciding factor, followed
by initial aortic diameter. Immediate OSR is the preferred treatment option in younger patients with a large initial aortic
diameter and in low-risk patients. Immediate TEVAR is preferred in elderly patients with a large initial aortic diameter
and in patients with a lower threshold for OSR. OMT should be considered in high-risk patients, in patients with small
initial aortic diameters, and in patients aged >80 years, unless their initial aortic diameter is >5.5 cm. However, the
differences in some patient groups are clinically insigniﬁcant, allowing a major role for patient preferences and hospital-
speciﬁc considerations. This clinical decision model may guide chTBAD treatment. (J Vasc Surg 2014;60:20-30.)Aortic dissection is a potentially fatal condition with a
mortality rate of up to 30%.1 Aortic dissections are usually
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usually within 2 to 5 cm of the left subclavian artery.”2
The optimal treatment option for patients with an un-
complicated chronic type B aortic dissection (chTBAD) is
controversial. Where the original debate had two posi-
tions, optimal medical therapy (OMT) with b-blockers3
and traditional open surgical repair (OSR),4 a third
treatment strategy, thoracic endovascular aortic repair
(TEVAR), has been increasingly used during the last 2 de-
cades. Good short-term results have been observed, with
relatively low perioperative morbidity and mortality.5-7
However, the reintervention rates after TEVAR are higher
compared with traditional OSR, and aortic rupture occurs
inw1.5% of patients after TEVAR during their remaining
lifetime.8
Unfortunately, no single treatment strategy is clearly
preferential, and level 1 evidence regarding treatment-
speciﬁc outcomes is lacking. The Investigation of Stent
Fig 1. Simpliﬁed bubble diagram shows interaction between health states for treatment of chronic type B aortic
dissection (chTBAD). Each health state has a possible transition to itself, which is not shown in this ﬁgure for clarity.
TEVAR, Thoracic endovascular aortic repair.
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ﬁrst randomized study to compare TEVAR, followed by
OMT vs OMT only, in patients with uncomplicated
chTBADs. This study showed no signiﬁcant difference
in rupture, survival, or reintervention after 2 years of
follow-up.9
The primary goal of this study was to assess the effect of
TEVAR, OSR, and OMT on the quality-adjusted life-years
(QALYs) for speciﬁc groups of patients with uncompli-
cated chTBADs with a decision-analysis model, synthesiz-
ing the best available evidence from the scientiﬁc
literature. The secondary objective was to provide a treat-
ment strategy decision tool for the surgeon, based on
four patient characteristics: age, sex, initial aortic diameter,
and surgical risk proﬁle.METHODS
Model and assumptions. A Markov cohort model
was developed to simulate hypothetical cohorts of patients
with chTBADs suitable for OSR and TEVAR, using Tree-
Age Pro 2012 software (TreeAge Inc, Williamstown,
Mass). A Markov model provides a convenient way of
modeling the prognosis for clinical problems with ongoing
risk. The model assumes that the patient is always in one of
a ﬁnite number of health states. All events are modeled as
transitions from one health state to another. Each state is
assigned a utility, a quality of life (QOL) value, and thecontribution of this QOL value to the overall outcome de-
pends on the length of time spent in the health state.10
Because of differences in natural history, patients with
connective tissue disorders, such as Marfan syndrome,
Loeys-Dietz syndrome, and Ehlers-Danlos syndrome,
among others, were not considered. Four different treat-
ment options were evaluated in this model: (1) immediate
elective OSR or (2) TEVAR, (3) OMT followed by OSR
(OMT-OSR), or (4) OMT followed by TEVAR (OMT-
TEVAR), if required for later complications. Indications
for intervention after OMT included an aorta diameter of
6.0 cm during follow-up, emergency repair for aortic
rupture, or other dissection-related complications requiring
intervention. In addition, treatment strategies were exam-
ined for use of different aortic diameter thresholds for sur-
gery during follow-up after OMT, including thresholds of
5.5 cm and 6.5 cm.11
For the Markov decision-analysis model, several
different health states were deﬁned for the four different
treatment strategies of chTBAD. The transitions between
the health states are shown in a simpliﬁed bubble-
diagram in Fig 1. The model cycled in 1-year cycles, and
transitions between the health states were based on proba-
bilities derived from an extensive search in the literature
(Table I). A discount rate of 3% per year was used to dis-
count future effectiveness.12
Patients in the ﬁrst treatment group, immediate elec-
tive OSR, could start in ﬁve different initial health states
Table I. Reference case probabilities and ranges for transitions to health states
Variables Reference case Range References
OSR
Technical success, % 95 90-100 4,21-24
Perioperative mortality rate, % 9.6 5.0-15 4,21-24
Perioperative complications OSR, %a 23 15-25 4,21-24
Stroke, % 5.8 3.0-7.0 4,21-24
Paraplegia, % 4.8 3.0-6.0 4,21-24
Renal failure, % 0.9 0.5-3.0 4,21-24
Other complications, % 11.5 5.0-15 4,21-24
Aortic complications, %b 2.1 1.0-5.0 4,21-24
Mortality after aortic complications, % 4.2 3.0-6.0 4,21-24
Need for reintervention, % 4.1 3.0-15 4,21-24
Rupture after OSR, % 0.2 0.1-1.5 4,21-24
Mortality after rupture, % 50 20-80 20
Perioperative mortality emergency intervention, % 19.8 15-25 4,21-24
TEVAR
Technical success, % 89.9 85-98 5,7-9,25-30
Immediate conversion to OSR, % 0.4 0.0-1.0 6,8-10,12,32-36
Perioperative mortality rate, % 3.2 1.0-10 5,7-9,25-30
Perioperative complications TEVAR, %a 19 15-25 5,7-9,25-30
Stroke, % 4.3 3.0-6.0 5,7-9,25-30
Paraplegia, % 0.8 0.5-3.0 5,7-9,25-30
Renal failure, % 2.6 1.5-4.0 5,7-9,25-30
Other minor complications, % 11.3 5.0-15 5,7-9,25-30
Aortic complications, %b 6.2 3.0-10 5,7-9,25-30
Mortality after aortic complications, % 5.1 3.0-7.0 5,7-9,25-30
Need for reintervention, % 14.3 10-25 5,7-9,25-30
Rupture after endovascular repair, % 1.2 0.5-4.0 5,7-9,25-30
Mortality after rupture, % 50 20-80 20
Perioperative mortality emergency intervention, % 19.8 15-25 5,7-9,25-30
OMT, %
Mean growth male, mm/y 1.2 0.0-2.5 31-34
Mean growth female, mm/y 3.3 0.0-4.5 31-34
Average yearly rupture rate
3.5-3.9 cm, % 0.1 0.05-0.3 32,34
4.0-4.9 cm, % 0.8 0.5-2.0 32,34
5.0-5.9 cm, % 1.9 1.0-5.0 32,34
$6.0 cm, % 3.7 2.0-10 32,34
Average yearly dissection ratec
3.5-3.9 cm, % 2.2 1.5-3.0 32,34
4.0-4.9 cm, % 2.0 1.5-3.0 32,34
5.0-5.9 cm, % 2.9 2.0-5.0 32,34
$6.0 cm, % 3.9 2.5-10 32,34
General variables
SMR rate for chTBAD Life-table .d 14,24
Males 1.97
Females 2.83
Excess mortality rate for chTBAD plus morbidity Life-table .d 14
Stroke, 3.62 16
Renal failure 3.2 17
Paraplegia 4.9 18
Discount rate, % 3 0-5 12
chTBAD, Chronic type B aortic dissection; OMT, optimal medical therapy; OSR, open surgical repair; SMR, standardized mortality rate; TEVAR, thoracic
endovascular aortic repair.
aPerioperative mortality deﬁned as 30-day mortality.
bAortic complications included extended or retrograde dissections, false aneurysms, and endoleaks.
cDissection extension causing problems (eg, malperfusion).
dNo range for standardized mortality rates and excess mortality of comorbidities was used.
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after OSR,” “stroke after OSR,” “paraplegia after OSR,”
“renal failure after OSR” and “dead.” Stroke, paraplegia,
and renal failure were chosen because these are clinically
the most relevant long-term morbidities after chTBADrepair.13 Almost all of the OSR cases were performed by
direct aortic repair with posterolateral thoracotomy.
Patients in the “good postoperative” state could
remain well without complications or could develop aortic
or dissection-related complications such as rupture,
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 1 Hogendoorn et al 23expanding dissection, recurrent pain, or false aneurysms.
These patients could die of these complications, or stay
alive. If they survived these acute complications, an emer-
gency reintervention was required. Patients could subse-
quently recover well, die of the reintervention, or develop
long-term morbidity. The same options were possible for
the patients in the “stroke,” “paraplegia,” and “renal fail-
ure” health states. However, we assumed that if a patient
in one of these health-states sustained another complica-
tion that led to long-term morbidity, they transitioned to
another health state: “multiple long-term morbidities.”
Once in this health state, the health of the patient was
decreased to a minimum, and we assumed that a third
long-term morbidity or complication would be equivalent
to death.
For the patients in the TEVAR treatment group, the
model structure was comparable with the OSR treatment
group, although there were some differences; for example,
patients could develop an endoleak or retrograde dissec-
tion. In addition, different probabilities for transitions
between the different health states (eg, risks of complica-
tions, aortic rupture rates) were used for the TEVAR treat-
ment group compared with the OSR treatment group.
Patients in the TEVAR and OSR group received computed
tomography follow-up every year.
Patients who started in the two conservative treatment
groups received OMT, with computed tomography
follow-up every 6 months. Once the patient developed
dissection-related complications (rupture, extended dissec-
tion, endoleak) or when the aortic diameter reached the
threshold for surgery according to the size criteria, they
required an emergency or elective intervention, respec-
tively. Risk for dissection-related complications depended
on the size of the aorta (Table I). Higher procedural risks
were used for emergency repair compared with elective
repair, as reported in the literature. A patient who under-
went OSR or TEVAR moved to the health states of the
OSR and TEVAR treatment group, as described above.
Mortality rates for men and women were obtained
from the Centers for Disease Control and Prevention Mor-
tality File.14 To adjust mortality for the chTBAD, the pa-
tients were subjected to excess mortality for presence of
chTBAD, independent of the treatment group. The excess
mortality was modeled higher in women than for men
because female sex is an important risk factor for long-
term mortality in patients with vascular disease.15 Patients
with long-term morbidities (stroke, renal failure, and para-
plegia) were subjected to a higher excess mortality due to
their reduced life expectancy.16-18
To perform an analysis for low-risk, medium-risk, and
high-risk patients, mortality rates and perioperative mor-
tality risk were adjusted by using a relative risk (RR).
Risk proﬁles included low risk (RR, 0.5), medium risk
(RR, 1), and high risk (RR, 2). For example, a low-risk
patient (RR, 0.5) had 50% less risk of death after both
OSR and TEVAR in elective and emergency settings
compared with the average risks for each of these situa-
tions. Furthermore, the complication rate was similarlyadjusted with the RR. The RR was tested over a wide
range (0.5-5).
OSR, TEVAR, and OMT. An extensive search was
performed using the MEDLINE database with a language
ﬁlter for English articles. The only articles that were consid-
ered eligible were those that described perioperative
morbidity and mortality for elective and emergency inter-
ventions, acute and long-term complications, technical
success, rupture, dissection and reintervention rates,
growth rates, rupture and dissection rates, and importance
of initial size of the aortic diameter of the descending aorta
performed with OSR or TEVAR. Furthermore, studies
were considered eligible if they (1) contained original data
and (2) were comparative studies, large single-treatment
studies (>10 patients), or described conservative manage-
ment of chTBADs.
All articles were subjected to critical appraisal as rec-
ommended by the Oxford Centre for Evidence Based
Medicine.19 The references of these articles were screened
for any missing relevant articles. Outcomes retrieved
from the 20 remaining articles were examined, evaluated
for consistency, and integrated into a weighted mean.
Furthermore, differences in natural course of the disease
regarding aortic growth and mortality rates for men and
women were determined to make the model speciﬁc for
unique patient situations. The reference case characteris-
tics were equal to the characteristics of patient data
retrieved from literature. All the rates, risks, and probabil-
ities were converted into annual probabilities and are
reported in Table I.4-8,20-34
QOL and interventions. To calculate the expected
QALYs, the number of cycles spent in each health state
was multiplied by the QOL value for the speciﬁc health
states. A slightly higher QOL was used for patients who
underwent repair than for patients treated with OMT
based on documented evidence in the literature.35,36 The
QOL values for patients with long-term morbidities
(stroke, paraplegia, and renal failure) were reduced ac-
cording to evidence from the literature regarding those
speciﬁc morbidities.37-39 For the interventions, disutilities
or “tolls” were included. These disutilities were applied
every time an intervention was required and were based on
the average recovery time for these interventions
(Table II). A wide range for all the QOL values was used to
explore the effect of the assumptions.
Data analysis. The reference case was a hypothetical
cohort of 55-year-old men with an uncomplicated
chTBAD with an initial aortic diameter of 5.0 cm and
medium risk for perioperative death. For patients under-
going OMT, a threshold for intervention during follow-up
was a maximum aortic diameter >6.0 cm (Table III).
Consistent with decision-modeling practice, the treat-
ment with the highest QALYs was considered the preferred
treatment option for patients with chTBADs. A difference
between two treatment strategies of <0.1 QALY, compara-
ble with <1.5 months in perfect health, was considered to
be clinically meaningless. After the reference case analysis,
deterministic one-way, two-way, and three-way sensitivity
Table III. Input variables for reference-case patient
Parameter Reference case Range
Sex Male Male/female
Age, years 55 50-100
Surgical risk category Medium Low-high
Initial aortic diameter, cm 5.0 3.5-6.5
Threshold for intervention, cm $6.0 5.5-6.5
Fig 2. Total expected quality-adjusted life-years (QALYs) at age
of presentation of (A) 50 to 70 years and (B) 70 to 90 years.
Thresholds indicate change in preferred treatment strategy: open
surgical repair (OSR), #60 years; thoracic endovascular aortic
repair (TEVAR), 60 to #70 years; and optimal medical therapy
(OMT) >70 years. OMT followed by TEVAR (OMT-TEVAR)
and OMT followed by OSR (OMT-OSR) are exactly equal in
panel (B).
Table II. Quality of life (QOL) values and disutilities for
interventions
Health state or
intervention
QOL
value Range tested Reference
Good postoperative
recovery
0.95 0.90-1.00 36
Conservative treated
chTBAD
0.93 0.90-1.00 36
Renal failure 0.49 0.40-0.55 37
Stroke 0.47 0.40-0.55 38
Paraplegia 0.45 0.40-0.55 39
Multiple morbiditiesa 0.20 0.10-0.30 Assumption
Dead 0.00
OSR 0.12 0.15 to 0.09 Assumption
TEVAR 0.05 0.08 to 0.02 Assumption
Acute complication 0.04 0.06 to 0.02 Assumption
chTBAD, Chronic type B aortic dissection; OSR, open surgical repair;
TEVAR, thoracic endovascular aortic repair.
aCombination of two of the following comorbidities: stroke, renal failure or
paraplegia.
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patient and procedural characteristics.
A probabilistic sensitivity analysis was performed using
10,000 random samples to assess the uncertainty around
the variable values using distributions of the values rather
than deterministic values. Probabilistic sensitivity analysis
can test the robustness of the results of a model in the pres-
ence of uncertainty and can also test the preferred treatment
based on the frequency of the selection show the preferred
treatment. Credibility intervals (CIs) in Bayesian ap-
proaches are analogous to conﬁdence intervals in frequent-
ist statistics. Finally, a clinical decision tool for treatment of
chTBADs was created as a chart based on four patient char-
acteristics: age, sex, maximum initial aortic diameter, and
low risk, medium risk, and high risk for surgery.
RESULTS
Reference-case. The reference case was simulated in
10,000 patients. OSR was the preferred treatment in 87%
of the samples for a 55-year-old man with an uncompli-
cated chTBAD and medium risk for perioperative mortal-
ity. The results of the analysis showed that this would result
in 10.06 QALYs (95% CI, 9.52-10.56 QALYs) after OSR,
followed by 9.92 QALYS (95% CI, 9.23-10.58 QALYs)
after TEVAR, which is similar to a difference of 2 months
in full health (95% CI, 0.21 to 0.47). OMT appeared
to be less desirable for these patients, with 9.64 QALYS(95% CI, 9.38-9.88 QALYS) for OMT-OSR, a difference
of 0.42 QALYs (95% CI, 0.01-0.81 QALYS), comparable
with 5.5 months in perfect health, and 9.40 QALYs (95%
CI, 9.11-9.69 QALYS) for OMT-TEVAR, a difference of
0.66 QALYs (95% CI, 0.17-1.12 QALYS) and comparable
with 8 months in perfect health.
Age. Age at the time of the decision was an important
factor in determining the optimal treatment strategy (Fig 2,
A and B). OSR is the preferred treatment until the age of
60 years, TEVAR is preferred for patients between 60 and
70 years, and OMT should be considered after the age of
70 years for patients with medium perioperative mortality
risks. The difference between OMT-OSR and OMT-
TEVAR was #0.01 QALY along the entire range when
patients were age $70 years. However, OMT as the initial
treatment strategy in patients $70 years resulted in QALYs
comparable with an additional 2.5 months in full health
JOURNAL OF VASCULAR SURGERY
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with initial OSR. Overall, age was the most important
determinant for optimizing treatment decisions because it
most frequently caused a change in preferred treatment
strategy, although the choice was also dependent on sex,
health of the patient, and initial maximum aortic diameter.
The interaction between these four variables and the
preferred treatment strategy for these patients is shown in
Fig 3.
Sex. For 55-year-old women, all other variables being
equal, OSR would yield higher QALYs (9.05 [95% CI,
8.61-9.45] QALYs) compared with TEVAR (8.94 [95%
CI, 8.40-9.34] QALYs). The difference between OSR and
TEVAR was 0.11 QALYs (95% CI, 0.19 to 0.41
QALYs), and therefore, this was a nonsigniﬁcant differ-
ence. Treating women with conservative management
would diminish their life expectancy in full health by almost
1 year: OMT-TEVAR, 8.30 QALYs (95% CI, 8.04-8.56
QALYs), and OMT-OSR, 8.02 QALYs (95% CI, 7.71-
8.32 QALYs). Compared with men, women generally have
1.0 QALY less to live at the moment of the treatment
decision for chTBAD, mainly due to the higher excess
mortality associated with chTBAD in women.
Perioperative mortality risk. Sensitivity analysis of
different categories of perioperative mortality risks in the
same reference-case patient showed that initial TEVAR
had the highest expected QALYs if the RR for periopera-
tive mortality was increased to 1.67. The beneﬁt of
TEVAR compared with OSR increased with higher RRs
(Fig 4). For 75-year-old male patients, OMT was the
optimal treatment strategy for all categories, including
patients with low perioperative mortality risks.
Maximum initial aortic diameter and threshold for
surgery. Size of the initial aortic diameter was an impor-
tant predictor of rupture and dissection. Therefore, a sensi-
tivity analysis was performed on the initial maximum aortic
diameter. Overall, patients with larger initial aortic diame-
ters had more beneﬁt from immediate intervention than
patients with smaller aortic diameters. The effect of initial
aortic diameter on optimal treatment strategy was sup-
ported by the outcomes for the range of maximum aortic
diameter thresholds for intervention that we evaluated in
the analysis (range, 3.5-6.5 cm). A patient with an initial
aortic diameter of 3.5 cm can expect 1.1 and 0.8 additional
QALYs with initial OMT compared with immediate repair
at the ages of 55 and 70 years, respectively. In contrast, pa-
tients with a very large initial aortic diameter (6.5 cm)
should always be operated on immediately, which leads
to an expected gain in QALYs of 1.1 (age, 55 years) and
0.7 (age, 70 years) compared with OMT (Fig 5). The
outcomes for ﬁve different patient groups are reported in
Table IV.
DISCUSSION
The current article presents a decision-analysis model
that showed that there is no “one-size-ﬁts-all” treatment
for uncomplicated chTBADs. Choice of optimal treatment
strategy depends on several important factors, includingage, sex, maximum aortic diameter, and perioperative mor-
tality risks. Overall, the model showed that very old pa-
tients ($80 years) should receive OMT, unless the initial
aortic diameter is >5.5 cm. Younger patients beneﬁt
more from immediate intervention, and particularly, the
perioperative mortality risks (low risk, medium risk, or
high risk) determine if OSR or TEVAR would be
preferred.
The Society for Vascular Surgery/American Associa-
tion for Vascular Surgery medical comorbidity grading sys-
tem can be used to categorize patients into the different
risk proﬁles. Initial aortic diameters of #3.5 cm should
generally be managed with OMT, independent of age of
the patient. Interestingly, female patients beneﬁt more
from immediate interventions than male patients. This
beneﬁt is mainly due to the higher aortic growth rate in fe-
male patients, whereby women reach the threshold for
intervention earlier than men do. Although this decision
model can provide more insight in the preferred treatment
for patients with chTBADs, several combinations of these
variables give a difference in treatment strategies
of <2 months, and patient preference should play a major
role in treatment decisions.
Decision analysis is an elegant method to study diseases
that involve different health states, can progress, and tran-
sition requiring treatment or interventions. The strength of
decision models is that one can perform a probabilistic
sensitivity analysis by using a wide range of the variables
instead of one ﬁxed number, which is particularly useful
in problems with uncertainty around the variables. Limita-
tion of most of the clinical studies is that these studies
mostly focus on one or two main outcomes such as overall
survival or adverse events. Although these are certainly
highly important outcomes, one must not only focus on
survival and adverse events. Other important factors, such
as QOL for long-term morbidities, rupture, and dissection
risks after >5 years, and the risk-proﬁle of the patient
should also be taken into account. These data are lacking
in most of these articles, although these results could highly
affect the decision of treatment for a patient with a
chTBAD.
This decision-analysis model considers all clinically rele-
vant basic patient characteristics that should be taken into
account before contemplating a decision about the treat-
ment. First, we assessed the variables that mostly inﬂuenced
the decision: age, sex, perioperative mortality risks, initial
maximum aortic diameter, and size criteria for intervention
during follow-up if OMT would initially be selected
(threshold of 6.0 cm). The latter is not a ﬁxed variable
but a choice based on general consensus in current clinical
practice. Subsequently, we selected subgroups and per-
formed analyses for all of these subgroups. The outcomes
in this model are fairly logical and compatible with
consensus that intervention should be avoided for small
maximum initial aortic diameters and old patients, whereas
interventions are more beneﬁcial for larger maximum initial
aortic diameters and younger patients. One of the goals of
this study was to create a treatment strategy decision tool in
Fig 3. This treatment strategy decision chart indicates optimal treatment strategy on the basis of four basic charac-
teristics: age, sex, surgical risk proﬁle, and maximum initial aortic diameter. Two treatment strategies in the same cell
(OSR/TEVAR, TEVAR/OMT, and OSR/OMT) indicate a difference of <2 months in quality-adjusted life-years
(QALYs). No diff indicates a difference of <2 months for all the treatment groups. The dotted box is the reference case.
TEVAR, Thoracic endovascular aortic repair.
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Fig 4. Total expected quality-adjusted life-years (QALYs) per risk
proﬁle of reference-case patient, a 55-year-old man. Low-risk pa-
tient: relative risk (RR), 0.5; medium-risk: RR, 1.0; high-risk: RR,
2.0. Increase of the patient’s risk proﬁle shows a shift from open
surgical repair (OSR) to thoracic endovascular aortic repair
(TEVAR). OMT-OSR,Optimal medical therapy followed by OSR;
OMT-TEVAR, OMT followed by TEVAR.
JOURNAL OF VASCULAR SURGERY
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model, requiring only basic patient characteristics, may
guide treatment strategies for patients with chTBADs.
However, other factors, such as extent of the dissection,
including its complexity and proximity to the origin of
the left common carotid and subclavian arteries, the num-
ber of fenestrations and potential compromise of the
visceral vasculature and aortoiliac bifurcations, may be
important determinants of whether TEVAR is feasible. In
addition, there will be patients who are not appropriate
candidates for aortic surgery of any kind. Finally, there
are patients in the OMT group who never have enlarge-
ment of the dissected aorta or complications during
follow-up. Therefore, treatment should be tailored to the
patient, and a patient-speciﬁc approach should be
performed.
Although decision analysis is a sophisticated method
to synthesize the best available evidence, this type of
analysis has some limitations. In this particular setting,
one of the limitations is that data were extracted from
published articles. We also observed that reporting was
subject to heterogeneity in the array and detail for inter-
ventions, outcomes, and the quality of reporting overall.
Although the data are not consistent across the entire
range of these studies, we tried to overcome this by
checking for consistency and integrating the evidence
into weighted means. Furthermore, we explored the in-
ﬂuence of the variables over wide ranges as determined
from results in literature.Second, the growth rates of aortic diameters are difﬁ-
cult to predict, and a wide range of yearly growth rates
across patient groups has been described.31-34 Further-
more, prediction of dissection-related complications is rela-
tively complex, and only absolute aortic diameters were
used in the analysis. In general, the faster the aortic diam-
eter is expanding, the earlier the intervention should be
performed. Patients who receive OMT should be assessed
every 6 months and should undergo an intervention if a
predeﬁned threshold for intervention is reached or when
the aorta grows relatively fast ($1 cm per year by
consensus).40 However, until the exact role of growth rates
and dissection-related complications are known, we should
use currently available evidence to its fullest extent to opti-
mize current treatment strategies.
QOL values were obtained from published articles, and
conservatively treated patients reported lower QOL values
than patients who received an intervention. However,
sensitivity analysis of this showed that even if QOL for
conservatively treated patients was higher for patients
who received an intervention, elective OSR and TEVAR
were still preferred over OMT (Fig 6). This emphasizes
the strength of this decision model. Finally, no QOL values
have been published for the health state “multiple morbid-
ities.” This QOL value was assumed to be lower than for
patients with one major morbidity and was tested over a
wide range (0-1), which did not result in a change of con-
clusions because only a very small percentage of patients
will end up in this health state.
Although several patient groups in the model had a
difference of >1.0 QALYs, the small difference in QALYs
for different treatment strategies for the reference-case
cohort is noteworthy. How much does a difference of
#2 months during long-term follow-up mean? Is it
worth surgical or endovascular intervention and associ-
ated costs? Does this mean there is no preferred strategy
in these speciﬁc categories? This will also depend on pa-
tient preferences. However, sensitivity analysis of the
tested variables showed a robust model and did not
signiﬁcantly change the recommended treatment strate-
gies. It is important to realize that a small difference in
QALYs is an average for the group; whereas, some pa-
tients may have a small beneﬁt, and others may have a
large beneﬁt. A mean difference of 0.14 QALY per pa-
tient is 1400 QALYs extra for a group of 10,000 patients;
thus, 1400 additional life-years in perfect health for the
whole group.
Decision analysis is a powerful tool to distinguish
preferred treatment strategies based on QALYs. Other
decision-analysis studies on surgical topics show similar
results, with small differences between treatment strate-
gies. Examples include evaluation of the beneﬁt of carotid
endarterectomy in asymptomatic patients compared with
symptomatic patients with severe carotid artery stenosis
(maximum <0.07 QALYs beneﬁt)41 and bare-metal vs
drug-eluting stents in percutaneous coronary interven-
tions (<0.014 QALYs).42 Decision analysis is especially
helpful for informed decisions in situations of uncertainty
Fig 5. Total expected quality-adjusted life years (QALYs) for maximum initial aortic size (in cm) of reference-case
patient, a 55-year-old man with chronic type B aortic dissection (chTBAD). Increase of the maximum initial aortic
diameter shows shift from optimal medical therapy (OMT) to intervention by open surgical repair (OSR) or thoracic
endovascular aortic repair (TEVAR). OMT-OSR, OMT followed by OSR; OMT-TEVAR, OMT followed by TEVAR.
Table IV. Outcomes of different treatment strategies for ﬁve patient groups
Reference-case patient and changed variablea Initial and changed variable OSRb TEVARb OMT-OSRb OMT-TEVARb
Male, 55 years, medium-risk, aortic diameter: 5.0 cm NA 10.06 9.92 9.64 9.40
Age, years 55/80 3.28 3.57 3.75 3.77
Risk Medium/high 8.59 8.74 8.41 8.12
Sex Male/female 9.05 8.94 8.30 8.02
Initial aortic diameter, cm 5.0/3.5 10.06 9.92 11.25 11.14
chTBAD, Chronic type B aortic dissection; NA, not applicable; OMT-OSR, optimal medical therapy followed by open surgical repair; OMT-TEVAR, optimal
medical therapy followed by thoracic endovascular aortic repair; OSR, open surgical repair; QALYs, quality-adjusted life-years; TEVAR, thoracic endovascular
aortic repair.
aExpected QALYs for the reference-case and subsequently for patients where the described parameter is changed compared with the reference case. Reference-
case patient: 55-year-old, medium-risk, male patient with a chTBAD and aortic diameter of 5.0 cm.
bOutcomes are described in QALYS. Preferred treatment is printed in bold. A difference of <0.1 QALYs is described as indifferent.
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controlled trials are lacking. Furthermore, decision anal-
ysis is particularly useful when the difference in outcomes
between strategies is small.
The purpose of this study was to design a decision tool
that can be used to guide the surgeon in determining the
preferred treatment option tailored to the individual pa-
tient with maximum number of QALYs as primary
outcome; therefore, associated costs were not analyzed.
However, because health care costs are increasing nation-
wide and political and societal focus on controlling health
care costs is increasing, a cost-effectiveness analysis should
be performed, and future studies should assess the total
costs and cost-effectiveness of the currently proposed treat-
ment strategies for chTBADs.The results of this model were based on the best avail-
able evidence in literature, and prospective evaluation of
the model will be needed. However, because a higher level
of evidence is currently lacking and treatment decisions
need to be made, this model, based on the best available
evidence, could guide treatment decisions for patients
with chTBADs.
CONCLUSIONS
This decision-analysis model shows that there is no
“one-size-ﬁts-all” treatment for uncomplicated chTBADs.
Age is the most important variable for determining preferred
treatment, followed by initial aortic diameter. This clinical
decision model can be used as a guide for the preferred
treatment option for different patients with chTBADs.
Fig 6. Total expected quality-adjusted life-years (QALYs) for
treatment of chronic type B aortic dissection (chTBAD) in the
reference-case patient (a 55-year-old man) with open surgical
repair (OSR), thoracic endovascular aortic repair (TEVAR), and
optimal medical therapy (OMT) per quality of life (QOL) for
conservative treated patients. Expected QALYs for OSR are always
higher than for TEVAR and OMT, and only OMT is affected by
QOL for conservative treatment.
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